| Literature DB >> 26038744 |
Laith Yakob1, Thomas V Riley2, David L Paterson3, John Marquess1, Archie Ca Clements4.
Abstract
Clostridium difficile is the leading cause of infectious diarrhea in hospitalized patients. Integrating several infection control and prevention methods is a burgeoning strategy for reducing disease incidence in healthcare settings. We present an up-to-date review of the literature on 'control bundles' used to mitigate the transmission of this pathogen. All clinical studies of control bundles reported substantial reductions in disease rates, in the order of 33%-61%. Using a biologically realistic mathematical model we then simulated the efficacy of different combinations of the most prominent control methods: stricter antimicrobial stewardship; the administering of probiotics/intestinal microbiota transplantation; and improved hygiene and sanitation. We also assessed the health gains that can be expected from reducing the average length of stay of inpatients. In terms of reducing the rates of colonization, all combinations had the potential to give rise to marked improvements. For example, halving the number of inpatients on broad-spectrum antimicrobials combined with prescribing probiotics or intestinal microbiota transplantation could cut pathogen carriage by two-thirds. However, in terms of symptomatic disease incidence reduction, antimicrobials, probiotics and intestinal microbiota transplantation proved substantially less effective. Eliminating within-ward transmission by improving sanitation and reducing average length of stay (from six to three days) yielded the most potent symptomatic infection control combination, cutting rates down from three to less than one per 1000 hospital bed days. Both the empirical and theoretical exploration of C. difficile control combinations presented in the current study highlights the potential gains that can be achieved through strategically integrated infection control.Entities:
Keywords: epidemiology; healthcare-acquired infection; infection control bundle; nosocomial; stochastic simulation; transmission model
Year: 2014 PMID: 26038744 PMCID: PMC4078791 DOI: 10.1038/emi.2014.43
Source DB: PubMed Journal: Emerg Microbes Infect ISSN: 2222-1751 Impact factor: 7.163
Figure 1Flow chart of selection process to identify relevant studies assessing the efficacy of C. difficile control bundles.
Figure 2Compartmental design of the stochastic, event-driven mathematical model of C. difficile transmission within a simulated 1000-bed acute care hospital.
Epidemiological model symbology and parameterization
| Symbol | Definition | Value (,vulnerable) | Control range | Reference |
|---|---|---|---|---|
|
| Develop into asymptomatic infectious (day−1) | 0.2,0.2 | 34 | |
|
| Colonization clearance in non-vulnerable (prop.) | 0.8 | 30 | |
|
| Develop symptomatic CDI (day−1) | 0.04,0.2 | 30 | |
|
| CDI self-resolve (proportion of cases) | 0.33 | 37 | |
|
| CDI self-resolve rate (day−1) | 0.5 | 38 | |
|
| CDI treatment (day−1) | 0.1 | 40 | |
|
| Treatment failure (proportion) | 0.2 | 41 | |
|
| Hospital admission (proportion) | 0.75,0.25 | 31,32 | |
|
| Mortality rate (day−1) | 0.0012 | 30 | |
|
| ||||
|
| Recovery of gut flora (day−1) | 0.011 | 0.011–0.1 | 34 |
|
| Antimicrobial treatment (day−1) | 0.1 | 0–0.1 | 31,32 |
|
| Transmission coefficient (day−1) | 0.5 | 0–1 | |
|
| Hospital discharge (day−1) | 0.17 | 0.17–0.34 | 33 |
Summary of the clinical studies examining the efficacy of control bundles in mitigating Clostridium difficile infection
| Study | Study population ( | Control bundle details | Effect size | |
|---|---|---|---|---|
| Bishop | Endemic strain unreported | Surgical inpatients (17, 145) | Resident rounding; hand hygiene; maintaining gastric acidity; antimicrobial stewardship | From 2.8/1000 to 1.8/1000 pd |
| Koll | Endemic strain unreported | Acute care inpatients >18 years across 35 hospitals (14, 591 CDI cases) | Contact precaution; hand hygiene; isolation; environmental cleaning | From ∼12/10 000 to ∼8/10 000 (hosp bed days) |
| Abbett | Endemic strain unreported | Acute care inpatients >18 years (881 CDI cases) | Contact precaution; hand hygiene; environmental cleaning; vancomycin | From 1.1/1000 to 0.66/1000 pd |
| Salgado | Epidemic strain unreported | Tertiary care inpatients >18 years (610 beds, 6 years) | Contact precaution; environmental cleaning; hand hygiene | From 1.8/1000 immediately post-epidemic to 1.2/1000 pd, 3 years thereafter |
| Weiss | Epidemic (NAP1/027) | Acute care inpatients (554 beds, 5 years) | Environmental cleaning; contact isolation; antimicrobial stewardship | From 37.3/1000 to 14.5/1000 (admissions) |
| Muto | Epidemic (NAP1/027) | Tertiary care inpatients (834 beds, 8 years) | Environmental cleaning; hand hygiene; contact isolation; antimicrobial stewardship | From 7.2/1000 to 3.0/1000 (hospital discharges) |
pd, patient days.
Figure 3The effect of control combinations on the ratio of patients discharged relative to those admitted with asymptomatic C. difficile colonization. Controls include: λ, rate of gut microbiota recovery which is expedited by probiotics or intestinal microbiota transplantation; α, rate of antimicrobial prescription which is reduced through stricter stewardship; β, the rate of transmission which is reduced through improvements to hygiene and sanitation; κ, the rate of patient discharge (inverse of average length of stay), which is increased to minimize patient exposure window.
Figure 4The effect of control combinations on C. difficile symptomatic disease incidence per 1000 hospital bed days. Controls include: λ, rate of gut microbiota recovery which is expedited by probiotics or intestinal microbiota transplantation; α, rate of antimicrobial prescription which is reduced through stricter stewardship; β, the rate of transmission which is reduced through improvements to hygiene and sanitation; κ, the rate of patient discharge (inverse of average length of stay) which is increased to minimize patient exposure window.